AI-Guided radiation aims to outsmart brain tumors
NCT ID NCT06492486
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 33 times
Summary
This study tests a new way to deliver radiation for diffuse gliomas, a type of brain tumor. Instead of a fixed dose, the radiation plan is adjusted mid-treatment based on MRI and PET scans, with help from artificial intelligence. The goal is to hit resistant tumor areas harder while protecting healthy tissue. Sixty adults with glioma will take part, and researchers will track tumor control and side effects over two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adaptive radiotherapy (radiation dose adjusted based on MRI and PET scans during treatment)
What this could lead to
If successful, this approach could make radiation therapy for brain tumors more precise, potentially improving tumor control and reducing side effects.
What could go wrong
This is a small, early-phase study (60 people) testing a complex workflow. It may not show clear benefits, and the AI component is still being developed.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.